Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Adenoviridae Infections × liposomal doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 48 Fallopian Tube Neoplasms 18 Breast Neoplasms 16 Neoplasms 14 Carcinoma, Ovarian Epithelial 11 Multiple Myeloma 7 Neoplasm Metastasis 6 Triple Negative Breast Neoplasms 3 Lung Neoplasms 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma 3 Solid Tumors 2 Recurrence 2 Peritoneal Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Liver Neoplasms 2 Kidney Neoplasms 2 Endometrial Neoplasms 2 Disease Progression 2 Vaccinia 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Sarcoma 1 Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1

Interventions

Gemcitabine 2 valrubicin 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 atezolizumab 1 Tumor Necrosis Factor-alpha 1 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Interferon-beta 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271318 2025-11-03

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡